Unknown

Dataset Information

0

Myocardial Viability Imaging using Manganese-Enhanced MRI in the First Hours after Myocardial Infarction.


ABSTRACT: Early measurements of tissue viability after myocardial infarction (MI) are essential for accurate diagnosis and treatment planning but are challenging to obtain. Here, manganese, a calcium analogue and clinically approved magnetic resonance imaging (MRI) contrast agent, is used as an imaging biomarker of myocardial viability in the first hours after experimental MI. Safe Mn2+ dosing is confirmed by measuring in vitro beating rates, calcium transients, and action potentials in cardiomyocytes, and in vivo heart rates and cardiac contractility in mice. Quantitative T1 mapping-manganese-enhanced MRI (MEMRI) reveals elevated and increasing Mn2+ uptake in viable myocardium remote from the infarct, suggesting MEMRI offers a quantitative biomarker of cardiac inotropy. MEMRI evaluation of infarct size at 1 h, 1 and 14 days after MI quantifies myocardial viability earlier than the current gold-standard technique, late-gadolinium-enhanced MRI. These data, coupled with the re-emergence of clinical Mn2+ -based contrast agents open the possibility of using MEMRI for direct evaluation of myocardial viability early after ischemic onset in patients.

SUBMITTER: Jasmin NH 

PROVIDER: S-EPMC8188227 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Myocardial Viability Imaging using Manganese-Enhanced MRI in the First Hours after Myocardial Infarction.

Jasmin Nur Hayati NH   Thin May Zaw MZ   Johnson Robert D RD   Jackson Laurence H LH   Roberts Thomas A TA   David Anna L AL   Lythgoe Mark F MF   Yang Philip C PC   Davidson Sean M SM   Camelliti Patrizia P   Stuckey Daniel J DJ  

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20210402 11


Early measurements of tissue viability after myocardial infarction (MI) are essential for accurate diagnosis and treatment planning but are challenging to obtain. Here, manganese, a calcium analogue and clinically approved magnetic resonance imaging (MRI) contrast agent, is used as an imaging biomarker of myocardial viability in the first hours after experimental MI. Safe Mn<sup>2+</sup> dosing is confirmed by measuring in vitro beating rates, calcium transients, and action potentials in cardiom  ...[more]

Similar Datasets

| S-EPMC6434939 | biostudies-literature
| S-EPMC10989678 | biostudies-literature
| S-EPMC3410562 | biostudies-literature
| S-EPMC4748952 | biostudies-other
| S-EPMC8186753 | biostudies-literature
| S-EPMC5629948 | biostudies-literature
| S-EPMC6855794 | biostudies-literature
| S-EPMC5876081 | biostudies-literature
| S-EPMC8272970 | biostudies-literature
| S-EPMC11258271 | biostudies-literature